Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction

2007 ◽  
Vol 106 (2) ◽  
pp. 375-380 ◽  
Author(s):  
Yanfang Li ◽  
Kevin W. Finkel ◽  
Wei Hu ◽  
Siqing Fu ◽  
Jihong Liu ◽  
...  
Keyword(s):  
Renal Dysfunction ◽  
Cancer Patients ◽  
Liposomal Doxorubicin ◽  
Gynecologic Cancer ◽  
Pegylated Liposomal Doxorubicin ◽  
Doxorubicin Treatment ◽  
Recurrent Gynecologic Cancer

Pegylated liposomal doxorubicin re-challenge in patients with ovarian cancer relapse: a multicenter retrospective study

2019 ◽  
Vol 29 (1) ◽  
pp. 153-157 ◽  
Author(s):  
Elisa Tripodi ◽  
Gennaro Cormio ◽  
Ugo De Giorgi ◽  
Giorgio Valabrega ◽  
Daniela Rubino ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Liposomal Doxorubicin ◽  
Objective Response ◽  
Pegylated Liposomal Doxorubicin ◽  
Complete Response ◽  
Recurrent Ovarian Cancer ◽  
Hematological Toxicity ◽  
Cancer Relapse ◽  
Platinum Agent

BackgroundPegylated liposomal doxorubicin (PLD) is an active and well-tolerable treatment in ovarian cancer relapse, either alone or in combination with other drugs. No data are available on the possibility to rechallenge PLD treatment in long survivor patients with recurrent ovarian cancer, as evaluated for platinum agent, paclitaxel and gemcitabine. The aim of the present study was to evaluate the anti-tumor activity and the toxicity profile of re-challenge of PLD in recurrent ovarian cancer patients.MethodsData on 27 patients with epithelial ovarian cancer treated in the last ten years (2007-2017) with palliative PLD rechallenge were included in this multicenter retrospective Italian study.ResultsThe objective response rate to PLD re-treatment were complete response in 19%, partial response in 30% and stable disease in 37%. Only 1 case of G4 hematological toxicity was reported. No patient experienced severe cardiac impairment (G2-4).ConclusionPLD rechallenge represents an active and safe possibility of treatment for long survivor ovarian cancer patients.

Single-agent pegylated liposomal doxorubicin (Caelix®) in chemotherapy pretreated non-small cell lung cancer patients: a pilot trial

Lung Cancer ◽  
2002 ◽  
Vol 35 (1) ◽  
pp. 59-64 ◽  
Author(s):  
Gianmauro Numico ◽  
Federico Castiglione ◽  
Cristina Granetto ◽  
Ornella Garrone ◽  
Gabriella Mariani ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Liposomal Doxorubicin ◽  
Single Agent ◽  
Pilot Trial ◽  
Pegylated Liposomal Doxorubicin ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document